CD4 and cancer: After the successful use of mRNA based vaccines during COVID-19 pandemic, and considering rapid production, scalability and ability to elicit both CD4+ and CD8+ T cell responses, mRNA based vaccine approaches for cancer immunoprevention has become an active area of investigation [75].